Date：April 24,2025
Agenda:
08:30-08:35 Opening remarks
08:35-09:00 Introduction to the work of UNICEF in promoting the localized production of pharmaceutical products in Africa
09:00-09:25 Progress in the localized production of vaccines in Africa
09:25-09:50 African vaccine production partnerships and the disease burden in Africa
09:50-10:15 Africa vaccine clinical trial landscape
10:15-10:30 Tea break
10:30-10:55 Experiences sharing of Chinese vaccine enterprises in the African market
10:55-11:40 Roundtable interview - Opportunities and challenges of localized supply in Africa
11:40-11:50 Discussion & Closing remarks
Speakers introduction:
Ms. Xiao Yi
Since joining UNICEF in 2022, Ms. Xiao Yi has been responsible for supplier capacity building, product innovation, market shaping between UNICEF's supply division and the China office, as well as promoting the localized production of medical supplies in Africa. Before joining UNICEF, Ms. Xiao Yi had already accumulated more than 10 years of professional experience in the procurement field. She has made outstanding contributions to projects such as the United Nations Development Programme's global emergency response project to the COVID-19 pandemic in 2019, the long-term agreements for global renewable energy innovative commodities and engineering services, and the United Nations' centralized procurement. She has obtained the MCIPS certification from the Chartered Institute of Purchasing and Supply(CIPS) and is committed to research on humanitarian supply chain management. She holds a master's degree and a doctorate degree in management.
Dr. Simone Blayer
Dr. Blayer oversees all vaccine process development and manufacturing activities for PATH and the nonclinical toxicology studies required to initiate first-in-human clinical trials. Based in Amsterdam, he is also a member of our Center for Vaccine Innovation and Access leadership team. For more than two decades, Dr. Blayer has worked in vaccine development and production in biotech and multinational pharmaceutical companies throughout Europe and Asia. He brings diverse industry experience in all aspects of chemistry manufacturing control, including vaccine process development and optimization; production at scale; technology transfer; facility engineering; project management and leadership; and business development. Prior to joining PATH in 2019, he founded the chemistry manufacturing control function at the Coalition for Epidemic Preparedness Innovations. As its first head, he led essential plans and activities for 26 separate vaccine projects. He was also the global project director for Batavia Biosciences in Leiden, the Netherlands. While there, he championed the RV3 rotavirus vaccine project in collaboration with Bio Farma and was an advisor to the Grand Challenges Inactivated Polio Vaccine Univercells project, among others. Dr. Blayer is an Italian-Israeli national and earned his PhD in biochemical engineering from University College London.
Dr. Zhang Yi
Doctor of Medicine, Associate Researcher, Supervisor of Master's Degree Candidates, Mainly engaged in the strategic planning of laboratories for highly pathogenic pathogenic microorganisms, as well as the establishment and application of new technology platforms such as pathogen detection and sequencing. Currently, mainly committed to the planning and implementation of the technical cooperation project in support of the Africa CDC, the formulation of the strategic plan for the headquarters laboratory of the Africa CDC, and the research on the development plan of the African laboratory network; leading the international health emergency response work on multiple occasions. Having presided over and participated in major special projects on infectious diseases and projects of the National Natural Science Foundation of China for many times. Having published more than 50 articles, and as a main contributor, won the Third Prize of Scientific and Technological Progress of the Chinese Preventive Medicine Association(CPMA) in 2017, and the Third Prize of Scientific and Technological Progress of Beijing. Assisted in the preparation of the Molecular Diagnostics Branch of China International Exchange and Promotive Association for Medical and Health Care(CPAM), and served as the Deputy Secretary-General and Committee Member of the association. As the committee member of the Travel Health Committee of CPMA. Selected into the Global Health Reserve Talent Pool of the National Health Commission.
Ms. Anne Nduta Mwangi
As a strategist reshaping clinical research in Africa through data-driven insights and bold partnerships. She drives clinical trial growth, stakeholder engagement, and ecosystem development across Sub-Saharan Africa. An experienced professional with a 20-year demonstrated history of working in clinical trials in EMEA with a sub-Saharan Africa. In the last 10 years, while based in sub-Saharan Africa, she have led initiatives that expand clinical trial activity, foster strategic collaborations with global health organizations and unlock opportunities in LMICs. Her work bridges the gap between data and decision-making, ensuring that every partnership and project contributes to sustainable, impactful health solutions. She thrives at the intersection of strategy, science, and partnerships; navigating complex regulatory landscapes, and championing clinical research innovation in emerging markets. Among the close collaborations are key strategic relationships with vaccine manufacturers, site management organizations, logistics and supply chain specialists.
Ms. Wendy Huang
She has 15 years’ experiences in pharma industry. She is the key person in International collaboration network building of Innovax, and contribute a lot in International business. She is familiar with vaccine lifecycle, programme management, vaccine WHO prequalification, and business development, etc. She has participated in HPV vaccine development, and served as the chief coordination in commercial tech-transfer. She participated in the drafting of the Technical Guidelines for Hepatitis E Vaccines by the ECBS Committee of the World Health Organization, also took a lead of the WHO prequalification programme. She was also involved in pharma-digital and AI solution exploration between 2022~24.
Ms. Li Meng
Li Meng has been leading CNBG's International Business Team since 2013, responsible for international organization relationships, regulatory affairs and oversea business development. She also serves as an Executive Committee member of EBPMN (Emerging Biopharmaceutical Manufacturers’ Network). With 20 years experiences in the biotechnology industry, she has successfully built an extensive network, bridging academia, NGOs, and global enterprises. Her adept navigation of international collaborations has led to the successful completion of several milestone projects. Among her achievements is the bOPV capacity expansion and prequalification initiative in partnership with the Bill & Melinda Gates Foundation (BMGF), which achieved WHO prequalification in 2019. She was involved in the establishment of CNBG's first joint venture and spearheaded CNBG’s first overseas acquisition. Li Meng and her team’s efforts have been pivotal in the global roll-out of the Covid-19 vaccine. She took a leadership role in establishing the partnerships for Phase III clinical trials across 6 countries and facilitating its registration in over 100 countries. She worked as a temporary advisor to the World Health Organization (WHO) inspectorate during its inaugural inspection of China's National Medical Products Administration (NMPA) in 2010. Furthermore, her leadership was acknowledged with her election to the executive committee of DCVMN, where she served from 2014 to 2016.
Mr. Wang Wenming
With more than 12 years of experience in the basic immunization industry, especially having a profound industry background in the field of vaccine cold chain. He has been committed to promoting the globalization process of China's vaccine cold chain, successfully raising China's vaccine cold chain technology and market share to a key position in the industry, and significantly improving the accessibility of vaccines in the "last mile" in remote areas. He once held several key positions in Haier Biomedical, including sales manager, director of R&D and Sales in the international department of vaccine cold chain, and general manager of the international business department. He has won honors such as "Pioneer of Entrepreneurship in Qingdao" and "Outstanding Youth on May 4th" of Haier Group.
Mr. Xu Zhipeng
Graduated from the major of Pharmaceutical Engineering at Wuhan University of Technology, holding the PMP certification. Since joining Tofflon in 2017, he has established the international bioprocess design department and the international BD team of Tofflon, and participated in the construction of several overseas subsidiaries and factories of Tofflon. He has 15 years of experience in the field of biopharmaceuticals. During his career, he has successively devoted himself to the delivery of multiple international overseas pharmaceutical engineering projects, including the construction projects of anti-tumor, complex injectable drug, and vaccine factories. In the field of drug technology transfer, he has contributed to the implementation of a number of international biopharmaceutical engineering EPC + technology transfer projects.
Original links: https://mp.weixin.qq.com/s/BAHg4D1beKcHS_05xDH4Eg
京公网安备 11010802041931号 © 2024 cpivc.com